Cited by 3,092Blood Pressure and Hypertension StudiesCardiovascular Health and Disease PreventionSodium Intake and Health

Treatment of hypertension in patients 80 years of age or older

Open access
Beckett, Nigel S., Peters, Ruth, Fletcher, Astrid E., Staessen, Jan A., Liu, Lisheng, Dumitrascu, Dan, Stoyanovsky, Vassil, Antikainen, Riitta L. +8 more·2008·New England Journal of Medicine

Abstract

BACKGROUND: Whether the treatment of patients with hypertension who are 80 years of age or older is beneficial is unclear. It has been suggested that antihypertensive therapy may reduce the risk of stroke, despite possibly increasing the risk of death. METHODS: We randomly assigned 3845 patients from Europe, China, Australasia, and Tunisia who were 80 years of age or older and had a sustained systolic blood pressure of 160 mm Hg or more to receive either the diuretic indapamide (sustained release, 1.5 mg) or matching placebo. The angiotensin-converting-enzyme inhibitor perindopril (2 or 4 mg), or matching placebo, was added if necessary to achieve the target blood pressure of 150/80 mm Hg. The primary end point was fatal or nonfatal stroke. RESULTS: The active-treatment group (1933 patients) and the placebo group (1912 patients) were well matched (mean age, 83.6 years; mean blood pressure while sitting, 173.0/90.8 mm Hg); 11.8% had a history of cardiovascular disease. Median follow-up was 1.8 years. At 2 years, the mean blood pressure while sitting was 15.0/6.1 mm Hg lower in the active-treatment group than in the placebo group. In an intention-to-treat analysis, active treatment was associated with a 30% reduction in the rate of fatal or nonfatal stroke (95% confidence interval [CI], -1 to 51; P=0.06), a 39% reduction in the rate of death from stroke (95% CI, 1 to 62; P=0.05), a 21% reduction in the rate of death from any cause (95% CI, 4 to 35; P=0.02), a 23% reduction in the rate of death from cardiovascular causes (95% CI, -1 to 40; P=0.06), and a 64% reduction in the rate of heart failure (95% CI, 42 to 78; P<0.001). Fewer serious adverse events were reported in the active-treatment group (358, vs. 448 in the placebo group; P=0.001). CONCLUSIONS: The results provide evidence that antihypertensive treatment with indapamide (sustained release), with or without perindopril, in persons 80 years of age or older is beneficial. (ClinicalTrials.gov number, NCT00122811 [ClinicalTrials.gov].).

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejmoa0801369

Cites

35 of 35 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • There is strong evidence from clinical trials of the value of treating hypertension in older adults.

    “There is strong evidence from clinical trials of the value of treating hypertension in older adults (70,71), with treatment of hypertension to individualized target levels indicated in most.”
  • There is strong evidence from clinical trials of the value of treating hypertension in older adults.

    “There is strong evidence from clinical trials of the value of treating hypertension in older adults (72,73), with treatment of hypertension to individualized target levels indicated in most.”

    From 13. Older Adults: Standards of Care in Diabetes—2025 (2025) · cites this paper as [72]

  • There is strong evidence from clinical trials of the value of treating hypertension in older adults.

    “There is strong evidence from clinical trials of the value of treating hypertension in older adults”

    From 13. Older Adults: Standards of Care in Diabetes—2026 (2026) · cites this paper as [79]

  • The extent to which HYVET data can be extrapolated to more fragile octogenarians is uncertain because HYVET patients were generally in good condition.

    “Because patients in the Hypertension in the Very Elderly Trial (HYVET) were generally in a good condition, 433 the extent to which HYVET data can be extrapolated to more fragile octogenarians is uncertain.”
  • There is strong evidence from clinical trials of the value of treating hypertension in the elderly.

    “There is strong evidence from clinical trials of the value of treating hypertension in the elderly (308,309).”

    From Standards of Medical Care in Diabetes—2009 (2009) · cites this paper as [309]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 1

  1. [35]35. receive immediate notification when a journal article is released early To be notified when an article is released early on the Web and to receive the table of contents of the Journal by e-mail every Wednesday evening, sign up through our Web site at www.nejm.org

Cited by

Sorted by citations

Authors
Beckett, N. S., Peters, R., Fletcher, A. E., Staessen, J. A., Liu, L., Dumitrascu, D., Stoyanovsky, V., Antikainen, R. L., Nikitin, Y., Anderson, C., Belhani, A., Forette, F., Rajkumar, C., Thijs, L., Banya, W., & Bulpitt, C. J.
Affiliations
  • Imperial College London (GB)
  • London School of Hygiene & Tropical Medicine (GB)
  • KU Leuven (BE)
  • Spitalul Clinic Județean de Urgență Cluj-Napoca (RO)
  • National Transport Hospital "Tzar Boris III" (BG)
  • The George Institute for Global Health (AU)
  • Hôpital Charles-Nicolle (TN)
  • Hôpital Broca (FR)
  • Brighton and Sussex Medical School (GB)
Venue
New England Journal of Medicine
Published
2008-05
Volume
358
Issue
18
Pages
1887-1898
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W2103881469
Cited by
3,092
References
35
Citations by year
2026: 61 · 2025: 96 · 2024: 99 · 2023: 103 · 2022: 157 · 2021: 118 · 2020: 149 · 2019: 167 · 2018: 173 · 2017: 208 · 2016: 207 · 2015: 203 · 2014: 230 · 2013: 191 · 2012: 225
FWCI
168.34
Type
journal article
Language
en
Open access
Locations
  • New England Journal of Medicine (publishedVersion)
  • PubMed (publishedVersion)
  • LSHTM Research Online (London School of Hygiene and Tropical Medicine) (acceptedVersion)
  • Lirias (submittedVersion, other-oa)
  • Figshare (submittedVersion, cc-by)
Funders
British Heart Foundation
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Health and Disease Prevention
  • Health Sciences › Nursing › Nutrition and Dietetics › Sodium Intake and Health
Keywords
hypertension, elderly patients, antihypertensive therapy, indapamide, perindopril, stroke prevention, systolic blood pressure, heart failure, cardiovascular mortality, adverse events, blood pressure targets, diuretics, ACE inhibitors, serious adverse events
MeSH terms
Aged, 80 and over, Angiotensin-Converting Enzyme Inhibitors, Antihypertensive Agents, Blood Pressure, Cardiovascular Diseases, Diuretics, Double-Blind Method, Drug Therapy, Combination, Female, Follow-Up Studies, Humans, Hypertension, Indapamide, Male, Stroke, Perindopril, Kaplan-Meier Estimate

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review